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ABSTRACT
Aims To evaluate outcome of anti-vascular endothelial 
growth factor (VEGF) therapy for the treatment of 
neovascular age-related macular degeneration (nAMD) 
in the real-life setting and to compare incidence of 
ocular serious adverse events (SAE) after injections 
administered by nurses and physicians.
Methods Retrospective, single-centre study. Medical 
records of patients receiving anti-VEGF treatment for 
nAMD between 2008 and 2013 with three-loading-
dose regimen were evaluated. Outcome measures 
were baseline visual acuity (VA), change in VA, number 
of intravitreal injections, incidence of ocular SAE and 
patients’ baseline characteristics affecting VA change. 
In addition, the number of injections per 1000 citizens 
living in the serving area and per individuals over 
65 years old were estimated.
Results 1349 eyes in 1117 patients received a total 
of 11 562 intravitreal anti-VEGF injections. Twenty-one 
per cent of patients received treatment for both eyes. 
The mean baseline Snellen VA was 0.32. The mean 
change of VA from baseline was +2, +2 and ±0 Early 
Treatment Diabetic Retinopathy Study letters and the 
mean numbers of injections were 5.7, 4.7 and 4.9 at 
years 1, 2 and 3, respectively. There was a negative 
correlation between baseline VA and change of VA. 
Incidence of endophthalmitis was 0.086%. No difference 
in the incidence of ocular SAE was identified between 
injections given by nurses or by physicians. The number 
of intravitreal injections per all citizens was 9 per 1000 
inhabitants and 45 per 1000 inhabitants over 65 years.
Conclusion The VA was maintained at the baseline 
level (±0 letters) with the mean of 15.3 anti-VEGF 
injections in real-world clinical practice during 3-year 
follow-up.
InTRoduCTIon
The development of vascular endothelial growth 
factor (VEGF) inhibitors has revolutionised the 
course of neovascular age-related macular degener-
ation (nAMD) by providing therapy to decelerate or 
even halt the progression of the disease.1 Four intra-
ocular anti-VEGFs have been used: ranibizumab 
(Lucentis, Genentech, San Francisco, California, 
USA), aflibercept (Eylea, Regeneron Pharmaceuti-
cals, Tarrytown, New York, USA) and pegaptanib 
sodium (Macugen,  Eyetech Pharmaceuticals/Pfizer, 
New York, USA) are registered for intraocular use, 
while bevacizumab (Avastin, Genentech) is widely 
used as an off-label drug in the treatment of nAMD. 
Pegaptanib was the first VEGF inhibitor approved 
for use in nAMD. However, patients experienced 
visual decline2 and pegaptanib use decreased after 
the more effective anti-VEGFs became available. 
Bevacizumab and ranibizumab have been shown to 
have similar efficacy and safety profiles in several 
randomised controlled trials (RCTs).3–7 Aflibercept 
has been shown to result in visual outcomes similar 
to ranibizumab.8 9
Fixed monthly ranibizumab and bevacizumab and 
bimonthly aflibercept (after 3 monthly injections) 
as well as pro re nata (PRN) regimen have resulted 
in visual acuity (VA) gain of 6–11 Early Treatment 
Diabetic Retinopathy Study (ETDRS) letters at 
2-year follow-up in RCTs.3 9–11 Less frequent moni-
toring and injections, in turn, have provoked dete-
rioration of outcome.12 13
The strict selection criteria in RCTs restrict their 
extrapolation to everyday practice: monthly clinic 
visits strain patients and healthcare providers, 
sometimes leading to infrequent treatment 
regimen. Understanding the real-world outcomes 
is essential to improve the therapy and to reduce 
overall costs. Recently, the Neovascular Age-Re-
lated Macular Degeneration Database study 
showed VA changes of +2, +1 and −2 ETDRS 
letters from baseline at years 1–3, and the AURA 
(Anti-vascUlar endothelial growth factor treatment 
Regimens in patients with wet Age-related macular 
degeneration) study +2.4 and +0.6 letters at years 
1–2, respectively.14 15
In the present study, the outcomes of anti-VEGF 
therapy for nAMD, the incidence rate of ocular 
severe adverse events (SAEs) after injections admin-
istered by nurses and by physicians and the number 
of annual injections per 1000 citizens and per 1000 
over 65-year-old citizens were assessed in real-life 
setting.
MATeRIAlS And MeThodS
Study design
A retrospective study was conducted in Tays Eye 
Centre (Tampere University Hospital, Finland). The 
anti-VEGF treatment protocol was modified PRN: 
outcome assessment after a loading dose of three 
intravitreal injections, and in case of inadequate 
therapeutic response or reactivations, treatment 
continuation with 3–6 injections. The injection 
and/or monitoring visits took place every 6–8 
weeks until November 2011 and thereafter every 
4–6 weeks. The treatment criterion was VA ≥0.1. 
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Table 1 Baseline characteristics of the eyes treated for AMD in 2008–2013 in Tays Eye Centre
First treated eye (n=1117) Second treated eye (n=232) All eyes (n=1349)
Age (years), median (IQR) 80 (74–84) 81 (77–85) 80 (75–84)
Female sex, n (%) 765 (68) 179 (77) 944 (70)
Baseline VA*, mean (SD) 0.30 (0.21) 0.42 (0.24) 0.32 (0.22)
Baseline VA*, n (%)
  <0.3 589 (53) 72 (31) 661 (49)
  0.3 – <0.5 297 (27) 75 (32) 372 (28)
  0.5 – <0.8 197 (18) 62 (27) 259 (19)
  ≥0.8 32 (3) 21 (9) 53 (4)
  Missing 2 (0) 2 (1) 4 (0)
*Snellen VA.
AMD, age-related macular degeneration; VA, visual acuity.
Nevertheless, the ophthalmologists were allowed to deviate 
from the protocol based on their own clinical judgement.
The electronic medical records of Tampere University Hospital 
were searched for all patients with International Classification of 
Diseases 10th Revision code for nAMD (H35.31) and ≥1 The 
Nordic Medico-Statistical Committee (NOMESCO) Classifica-
tion of Surgical Procedures (NCSP) code for intravitreal injec-
tion (CKD05) between 1 January 2008 and 31 December 2013. 
The study was restricted to treatment-naïve eyes undergoing 
monotherapy with ≥1 anti-VEGF injection for nAMD during 
the above-mentioned period (see online supplementary figure 
1). Switching between anti-VEGF compounds was allowed. 
Exclusion criteria were treatment initiation before 2008, anti-
VEGF injection for other reasons than nAMD and use of laser 
photocoagulation, photodynamic therapy or intravitreal steroid.
As this study was retrospective in nature and patient identi-
fiers were stripped out completely after the data collection, the 
ethics committee of Pirkanmaa Hospital District determined 
that formal ethics approval was not required. The study was 
conducted in accordance with the Declaration of Helsinki.
data collection
A pilot study was conducted on patients with birthday divisible 
by 5 (n=203), whereafter the data collection expanded to cover 
the entire study population. For the studied eyes, data were 
collected from diagnosis date to end of treatment and/or moni-
toring or until 31 December 2013, including intravitreal injec-
tion and monitoring visits and ocular SAEs (endophthalmitis, 
retinal detachment or traumatic cataract). Fellow eyes with VA 
≥0.1 and no prior nAMD treatment were identified (excluding 
the pilot study group) for the analysis of nAMD incidence in the 
second eye.
VA is reported as Snellen unless otherwise stated, measured 
using refraction, habitual correction, pinhole or a combination. 
For comparison to previous studies, Snellen to ETDRS conver-
sion was done using the formula 85+50*log(Snellen fraction) 
(described previously).16 Very low VA measurements were anal-
ysed by substituting counting fingers with 0.025 and hand move-
ments or light perception with 0.01.
outcome measures
The main outcome measure was VA change at 1, 2 and 3 years 
from baseline. Other outcome measures were baseline charac-
teristics affecting VA change, number of intravitreal injections 
given each treatment year, number of injections given by nurses 
and by physicians, incidence of SAEs, number of different anti-
VEGFs used and nAMD incidence in the second eye. In addition, 
the numbers of injections per 1000 citizens and per 1000 over 
65-year-old citizens living in Pirkanmaa Hospital District were 
estimated.
Statistical methods
The overall study population consisted of patients that received 
≥1 anti-VEGF injection. The effectiveness analysis sets consisted 
of eyes with completed follow-up of 1, 2 and 3 years. Snellen VA 
was used as a continuous variable. To account for missing data, 
Last-Observation-Carried-Forward (LOCF) analysis was used. If 
there was no VA available from the visit of treatment decision, 
the baseline VA was taken from a prior visit within 1 month, or 
secondarily from the first injection visit if available.
ReSulTS
Baseline characteristics
The baseline characteristics are presented in table 1. During the 
6-year study period, 1349 eyes in 1117 patients were treated 
with 11 562 intravitreal anti-VEGF injections. Of these patients, 
232 (21%) received treatment for both eyes. Within 2 years of 
first eye nAMD diagnosis, 18% received treatment also for the 
second eye (see online supplementary figure 2).
Female preponderance of the patients was 2.2:1 and 1.9:1 
after adjusting for national data for sex ratios in people over 
50 years. The number of eyes entered into the study doubled 
from 2008 to 2013 (table 2). Mean baseline VA was lower in 
the first treated eyes than in the second treated (0.30 vs 0.42) 
and increased from 0.29 in 2008 to 0.35 in 2013. Most eyes did 
not meet the European Union (EU) driving standards (baseline 
VA ≥0.5).
The population of Pirkanmaa Hospital District was 497 002 
in 31 December 2013, of whom 19.2% (95 424) were ≥65 year 
olds (Finnish Statistics of Medicines 2013). The number of 
injections in 2013 was 9 per 1000 inhabitants and 45 per 1000 
≥65-year-old inhabitants living in the serving area.
Intravitreal injections
Altogether, bevacizumab was given in 10 884 and ranibizumab 
in 583 injections (table 3). Bevacizumab was the most commonly 
used anti-VEGF each year since its introduction in 2009. Ranibi-
zumab use declined rapidly after it was the most common anti-
VEGF in 2008 (86%). Pegaptanib was used only until 2009 and 
aflibercept only during 2013. While physicians performed all 
injections in 2008, already in 2012, nurses performed 99% of 
injections (table 3).
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Table 3 Distribution of injections by compound, administrator and by year
Year
2008 2009 2010 2011 2012 2013 Total
n % n % n % n % n % n % n %
Anti-VEGF
  Bevacizumab 0 0 807 84 1367 100 1791 100 2671 99 4248 98 10 884 94
  Ranibizumab 361 86 127 13 1 0.1 2 0.1 16 0.6 76 2 583 5
  Pegaptanib sodium 59 14 30 3 0 0 0 0 0 0 0 0 89 0.8
  Aflibercept 0 0 0 0 0 0 0 0 0 0 6 0.1 6 0.1
Total 420 100 964 100 1368 100 1793 100 2687 100 4330 100 11 562 100
Administrator
  Physician 420 100 961 100 260 19 74 4.1 21 0.8 77 1.8 1813 16
  Nurse 0 0 3 0.3 1108 81 1719 96 2665 99 4251 98 9746 84
  NA 0 0 0 0 1 2 3
Total 420 100 964 100 1368 100 1793 100 2687 100 4330 100 11 562 100
NA, not available; VEGF, vascular endothelial growth factor.
The mean numbers of injections were 5.7, 4.7 and 4.9 during 
completed treatment years 1–3, respectively (table 2). During 
the study period, the number of injections given during the first 
year increased gradually (4.9 injections in eyes first treated in 
2008 to 6.8 in 2012). Similar increase was observed for years 
2–3.
Change of VA from baseline
Change of VA from baseline at 1, 2 and 3 years was analysed 
for eyes that completed respective follow-ups (Effectiveness 
analysis sets; LOCF analysis). The change from baseline was +2, 
+2 and ±0 ETDRS letters at years 1–3, respectively (table 2). 
Completing the yearly follow-ups was equally common for the 
first and second treated eyes, although the first appeared to 
retain their VA slightly better. Treatment initiation year did not 
affect the change of VA.
The largest benefit was seen in patients with low baseline VA 
(figure 1, table 2). In the eyes with baseline VA <0.3, there was 
an increase of 14 letters at 3 years. In contrast, VA appeared to 
decline in eyes with baseline VA ≥0.3: the better the baseline 
VA, the bigger the observed decline. There was an increasingly 
negative correlation between baseline VA and change of VA from 
baseline (table 2). In contrast, neither gender nor baseline age 
were shown to have a statistically significant association with 
change of VA from baseline.
As clinical trials have strict inclusion criteria for baseline VA 
that is associated with VA gain, subgroup analyses were made 
to test whether implementing these would affect the visual 
outcomes in the present study. In the present study, 947 eyes 
(70%) met the inclusion criteria, best corrected visual acuity 
0.065–0.5 Snellen equivalent, of the pivotal clinical trials of 
ranibizumab and aflibercept (Minimally Classic/Occult Trial 
of the Anti-VEGF Antibody Ranibizumab in the Treatment of 
Neovascular AMD (MARINA), Anti-VEGF Antibody for the 
Treatment of Predominantly Classic Choroidal Neovascular-
ization in AMD (ANCHOR), Vascular Endothelial Growth 
Factor VEGF Trap-Eye: Investigation of Efficacy and Safety in 
Wet Age-Related Macular Degeneration (VIEW)).9–11 In this 
subgroup, mean baseline Snellen VA was 0.28 equalling to 58 
ETDRS letters and VA change was +4, +5 and +4 letters at 
years 1–3, respectively (table 4). Implementing the inclusion 
criteria of The  Comparison of Age-Related Macular Degen-
eration Treatment Trials (CATT) study,3 1146 eyes (85%) had 
Snellen VA 0.065–0.8. Mean baseline was 0.35 (62 letters), and 
change at years 1–3 was +2, +2 and ±0 letters. The injection 
frequency and baseline age of both subgroups were similar to the 
whole study population (table 4).
Serious adverse events
The incidence of ocular SAEs was 0.104% (12/11562 injec-
tions), including 10 endophthalmites (0.086%), two retinal 
detachments (0.017%) and no traumatic cataracts. There was no 
statistically significant difference in the incidence of SAEs after 
injections given by nurses (10 per 9746 injections, 0.103%) or 
physicians (2 per 1813, 0.110%) (p=0.93).
After the treatment of endophthalmitis, VA turned out at least 
at the same level it was before the endophthalmitis in seven out 
of 10 eyes. In the remaining three eyes with endophthalmitis, 
VA remained at a lower level than before the endophthalmitis 
(Snellen VA declining from 0.4 to 0.25, from 0.25 to counting 
fingers and 0.05 to counting fingers, respectively).
Treatment and follow-up discontinuation
The treatment and follow-up was discontinued before the end 
of 2013 in half of all cases (n=654). The reason was poor treat-
ment response in 47% of those and disease inactivation in 27% 
(figure 1). Other reasons were worsening of overall health status 
(8%), patient declined treatment (8%), death within 1 month 
(3.2%) and other/unknown (8%).
Discontinuation for any reason occurred most often in the 
baseline VA <0.3 group (61%, n=402). In eyes with baseline VA 
0.3–<0.5, 0.5–<0.8 and ≥0.8, the rate varied between 36% and 
38%. Moreover, the follow-up of eyes with baseline VA <0.3 
was more often discontinued due to poor treatment response 
(61%) than that of eyes with baseline VA ≥0.3 (between 21% 
and 26% in each group). In groups with baseline VA >0.3, 
disease inactivation was more frequent than poor treatment 
result (figure 1). In the lowest baseline VA group, discontinu-
ation occurred over threefold more frequently from poor treat-
ment response compared with disease inactivation (243 vs 64).
dISCuSSIon
This retrospective study shows the anti-VEGF treatment for 
nAMD using modified PRN regimen and mostly bevacizumab 
(94%) resulting in stabilisation of VA for at least 3 years in real-
life setting. Although VA was maintained, the initial gain was 
lower than in clinical trials with fixed monthly treatment and/
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Figure 1 (A) Graph showing mean visual acuity (VA) and number of eyes over time in subgroups of different baseline VA. Snellen VA at baseline 
and at 1, 2 and 3 years stratified by baseline VA. (B) Reasons for treatment and follow-up cessation before the end of 2013 in subgroups of eyes with 
baseline Snellen VA<0.3, 0.3-<0.5, 0.5-<0.8 and ≥0.8.
or monitoring.3 9–11 However, the visual outcome was in accor-
dance with previous real-life studies.14 15 17 Poor VA gain has 
been associated with low injection and monitoring frequency.18 19 
Protocols of clinical trials have proven challenging to follow 
in practice; the injection frequency in the previous real-life 
studies14 15 17 as well as in the present study were lower than in 
clinical trials.
Mean baseline VA and age were higher than in most clinical 
trials,3 9–11 both known to be associated with VA gain.14 18 In the 
present study, negative correlation was confirmed for baseline 
VA although not for age. The poor VA gain in eyes with good 
baseline VA may originate from a ceiling effect.
In the subgroup of eyes that met the criteria of MARINA, 
ANCHOR and VIEW,9–11 mean baseline VA was lower compared 
with the whole study population, although slightly higher than 
in these trials (table 4). There was a clear VA gain, although 
slighter than in clinical trials. Implementing the inclusion criteria 
of CATT3 in the present study, mean baseline VA was higher 
than that of whole study population or CATT bevacizumab PRN 
treatment arm, but the mean change from baseline remained 
unchanged.
Tays Eye Centre was the first hospital in Finland and among 
the first ones internationally to train nurses to give intravitreal 
injections. Initiated in 2009, this practice was soon adopted as 
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Table 4 Visual outcomes and number of injections in anti-VEGF treatment studies
Study
Baseline Year 1 Year 2 Year 3
n Age (years) VA* n
Change of 
VA*† IVI n Change of VA*† IVI n
Change of 
VA*† IVI
MARINA‡ 77 54 +7 monthly +7 monthly NA NA
ANCHOR‡ 76 47 +11 11.2 +11 10.1 NA NA
VIEW studies§ 76 54 +8 7.5 +8 3.6 NA NA
CATT¶ 79 60 +6 7.7 +5 6.4 NA NA
AURA 77 55 +2 5 +1 2.2 NA NA
Tufail et al 2014 79 55 +2 5 +1 4 −2 4
Current study¶**
  All eyes 1345 80 60 733 +2 5.7 349 +2 4.7 193 ±0 4.9
  Baseline VA 0.065–0.5 947 80 58 539 +4 5.8 245 +5 4.8 131 +4 5.0
  Baseline VA 0.065–0.8 1146 80 62 663 +2 5.7 314 +2 4.7 173 ±0 5.0
*All VA scores in Early Treatment Diabetic Retinopathy Study letters IVI.
†Change of VA from baseline.
‡Ranibizumab 0.5 mg monthly treatment arm (Brown et al 2006; Rosenfeld et al 2006).
§Aflibercept treatment arm (Heier et al 2012).
¶Bevacizumab pro re nata treatment arm (Martin et al 2011).
**Last-Observation-Carried-Forward analysis.
IVI, intravitreal injections; NA, not available; VA, visual acuity.
routine: nurses administered 81%–99% of injections per year in 
2010–2013. There was also a rapid shift from using ranibizumab 
to bevacizumab and an increase in injection frequency during 
the study period. Yet the VA change from baseline remained 
similar, even though a correlation between visual outcome and 
injections frequency has been previously observed.15 However, 
this discrepancy may relate to the inverse association between 
VA change and baseline VA, and the simultaneous increase in 
injections frequency and baseline VA. The increase in baseline 
VA may refer to treatment initiation at earlier stage of nAMD 
towards the end of the study period. This, in turn, may indi-
cate increased awareness of treatment availability resulting in 
patients seeking treatment earlier or faster diagnosing after the 
onset of symptoms.
Treatment discontinuation rates have been shown to be high 
in real-life clinical practice.14 15 17 20 The proportion of eyes lost 
to follow-up was 47% in AURA study at year 2 and 78% in the 
Neovascular Age Related Macular Degeneration Database study 
at year 3.14 15 In the USA, discontinuation rates among Medi-
care beneficiaries were 57% and 71% within 12 and 24 months, 
respectively.20 In the present study, follow-up was discontinued 
in 48% of the eyes before the end of 2013, the rate being 
highest in eyes with baseline VA <0.3 (61%; subgroups with 
VA ≥0.3, 36–38%). The most common reason was poor treat-
ment response in eyes with baseline VA <0.3 and inactivation of 
disease in other VA groups. This suggests that early treatment 
initiation leads more likely to inactivation of nAMD. On the 
other hand, the eyes that were diagnosed at rather progressive 
stage (VA <0.3) and continued in treatment had the biggest VA 
increase from baseline. These patients are likely to appreciate 
the treatment even when the progression of the disease is slowed 
down or halted, retaining at least part of their vision.
The introduction of anti-VEGF injections for nAMD has placed 
a sudden and extensive treatment burden on healthcare systems. 
In Tays Eye Centre, the number of injections increased 10-fold 
from 2008 to 2013. Injections by nurses were introduced in 2009 
to provide treatment for all patients in need. Our retrospective 
analysis shows that this change in policy did not change the inci-
dence of SAEs, which is in accordance with previous reports.21 22 
Furthermore, the present study indicated no difference in VA 
change related to injections given by physicians or nurses, nor 
related to the use of ranibizumab or bevacizumab.
In Finland, bevacizumab is the most commonly used anti-
VEGF drug for nAMD due to its affordability. The present study 
outcome may be considered a real-life outcome of bevacizumab 
in nAMD, as bevacizumab accounted for 94% of injections. This 
suggests that VA outcomes of bevacizumab and ranibizumab are 
similar also in real-life clinical practice in a large, unselected 
patient population. The PRN treatment protocol appears more 
cost-effective than monthly bevacizumab, as small increases in 
effects incur higher additional costs.23 Furthermore, bevaci-
zumab appears more cost-effective than ranibizumab and afliber-
cept given as needed or monthly.23
Previously, numbers of nAMD injections per total population 
or per population of ≥65 year olds have been scarcely reported. 
For 2011, the number of injections in southern Finland (using 
mainly bevacizumab) was twofold to threefold higher than 
that in southern Sweden (using ranibizumab).24 The Swedish 
Medical Retina experts assumed that the difference originates 
from stricter indications for initiating nAMD treatment. It is 
unlikely that the nAMD prevalence would vary twofold to three-
fold in neighbouring Nordic countries. In the USA, the rate of 
fee-for-service Medicare beneficiaries aged ≥65 years receiving 
intravitreal injections varied by sevenfold across states, ranging 
from 4/1000 (Wyoming) to 28/1000 (Utah), average 19/1000.25 
In the present study, in 2013, the number of intravitreal injec-
tions for nAMD per population living in the serving area was 
9/1000 inhabitants and 45/1000 inhabitants aged ≥65 years, 
which is over twofold higher than that reported in the USA.
The efficacy of anti-VEGF treatment in nAMD has been shown 
in several RCTs.3–6 8–11 Although RCTs are the gold standard 
for evaluating outcomes of medical interventions, their strictly 
defined study populations may not include all the patients that 
would actually receive the drug in clinical practice, and the stan-
dardised conditions often differ from real-life settings. Due to 
these discrepancies in patient selection, treatment conditions and 
regimens, both the effectiveness and potential risks/side effects 
of the therapy may be different and, thus, the results of RCTs 
may not be directly translated into decision making in clinical 
practice. The present retrospective study shows stabilisation of 
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VA in response to anti-VEGF therapy, although with substantially 
lower numbers of annual anti-VEGF injections than in RCTs.
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